Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). This ...
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from two clinical trials of nadunolimab combination therapy ...
STOCKHOLM, March 17, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, ...
TAMPA, FL / ACCESSWIRE / November 8, 2023 / Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor ...
The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a ...
Additional intellectual property protection reinforces the strategic value of IP-001 and supports ongoing clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results